What's Happening?
Researchers at the Mayo Clinic and University of Texas MD Anderson Cancer Center have developed an AI model named REDMOD, which has shown significant promise in detecting pancreatic cancer much earlier than current methods. The AI was tested on CT scans
and successfully identified the most common form of pancreatic cancer approximately 16 months before diagnosis in nearly 75% of cases. This is nearly double the detection rate of specialists without AI assistance. REDMOD works by identifying subtle radiomic patterns in tissue that are often missed by the human eye. The model was trained on 969 CT scans and tested on additional scans, demonstrating a high level of accuracy and consistency across different clinical settings.
Why It's Important?
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths in the U.S. by 2030, largely due to late-stage diagnoses. The development of REDMOD could significantly alter this trajectory by enabling earlier detection, potentially when the disease is still curable. This advancement could lead to improved survival rates and reduced healthcare costs associated with late-stage cancer treatments. The AI's ability to detect cancer early could also pave the way for more personalized and timely treatment plans, benefiting patients and healthcare providers alike.
What's Next?
The researchers plan to test REDMOD on larger and more diverse populations to ensure its effectiveness across different demographics. They also aim to integrate the AI into existing medical processes, which could involve training healthcare professionals to use the technology effectively. If successful, REDMOD could become a standard tool in cancer diagnostics, shifting the focus from late-stage treatment to early intervention.
